In re: Casella Waste Systems, Inc. No. 296-5-02 (Superior Court of Vermont, Washington Cty, May 22, 2002)
Investigation into Casella Waste Systems potential monopolization. In 2011, Casella paid $1 million fine for violations of the settlement
In re Antibiotic Antitrust Actions, 410 F. Supp. 669, 1974 U.S. Dist. LEXIS 9407 (D. Minn. 1974)
Plaintiff States sought damages and injunctive relief, alleging that Defendant companies conspired to monopolize and restrain the trade for the manufacture, sale and distribution of broad spectrum antibiotics (BSA).
New York v. Microsoft Corp., 97 F. Supp. 2d 59 (D.D.C. 2000)
U.S. Department of Justice and the Plaintiff States alleged that the Defendant, Microsoft Corporation violated State and Federal law by maintaining a monopoly in the market for Intel-compatible personal computer operating systems and by illegally tying its Windows operating system to its Internet Explorer browser.
U.S. v. Sony Corporation of America, 1998 U.S. Dist. LEXIS 20815, 2000-1 Trade Cas. (CCH) 72,787 (S.D.N.Y. 1998)
U.S. and the States sought to enjoin Loews Theatres, Inc. (Loews) and Cineplex from consummating their merger, arguing that the merger would significantly impair competition in first screening movie theaters.
In re Clozapine Antitrust Litigation, MDL No. 874 (N.D. Ill. 1991)
Plaintiff States sought monetary damages and injunctive relief against Sandoz Pharmaceuticals Corporation (Sandoz), alleging the company unlawfully required those who purchased its drug, Clozapine, to also purchase distribution and patient monitoring services from Sandoz.
In re: Buspirone Antitrust Litigation,Case No. 01 CV 11401, MDL 1410, MDL 1413 (S .D.N.Y.) (see also Ohio v. Bristol Myers Squibb
Plaintiff States sought damages and injunctive relief, alleging that Bristol-Myers Squibb Co. (BMS) attempted to maintain an unlawful monopoly on buspirone hydrochloride, a medication used to treat generalized anxiety. In settling, BMS agreed to a stipulated injunction and to reimburse consumers and state and local public entities for overcharges. In 2008, plaintiff states sued BMS for failing to report accurately to the states, pursuant to the settlement, a patent arrangement involving the drug Plavix. The company pleaded guilty to lying to the FTC and the states recovered $1.1 million in fines.
In re Cardizem CD Antitrust Litigation 99-MD-1278 (E.D. Mich. Jan. 29, 2003), 332 F.3d 896 (6th Cir. 2003)
Plaintiff States sought damages and injunctive relief, alleging that defendants entered into an unlawful agreement attempting to delay or prevent the marketing of less expensive generic alternatives to Cardizem CD, a brand name drug used to prevent heart attacks. The Plaintiff States settled for $80 million, the bulk of which was to be used to reimburse purchasers including consumers, insurance companies and other third-party payers for overcharges paid for Cardizem CD between 1998 and 2003.
In Re: Toys ‘R’ Us Antitrust Litigation, 191 F.R.D. 347 (E.D.N.Y. 2000); M.D.L. 1211
Plaintiff States alleged that Toys R Us entered into vertical and horizontal agreements with numerous toy manufacturers to limit the supply of certain popular toys to warehouse clubs.
Ohio, et al, v. Bristol-Myers Squibb Co., et al.(D.D.C. 2002); see also In re Buspirone Antitrust Litigation,Case No. 01 CV 11401, MDL 1410, MDL 1413 (S .D.N.Y.)
Plaintiff States sought damages and injunctive relief, alleging that the drug company, Bristol-Myers Squibb, Co. (BMS) wrongfully maintained a monopoly on Taxol, a drug for which the Plaintiff States alleged Defendant fraudulently filed a patent. BMS’s alleged wrongful action delayed entry into the market by generic competitors of the drug, resulting in higher prices for Taxol. In 2008, plaintiff states sued BMS for failing to report accurately to the states, pursuant to the settlemen, a patent arrangement involving the drug Plavix. The company pleaded guilty to lying to the FTC and the states recovered $1.1 million in fines.
California, et al., v. Chevron Corporation and Texaco, Inc. No. 01-07746 (E.D. Cal. Sept. 10, 2001)
Plaintiff States sought to enjoin Chevron Corporation (Chevron) and Texaco, Inc. (Texaco) from consummating their merger, arguing that the merger would significantly impair competition in the markets for refining, wholesaling, and retailing of gasoline and other motor vehicles; aviation gasoline and jet fuel; and California crude oil.
